Zobrazeno 1 - 10
of 33
pro vyhledávání: '"May E. Venturanza"'
Autor:
Andrew Blauvelt, Jacek C. Szepietowski, Kim Papp, Eric L. Simpson, Jonathan I. Silverberg, Brian S. Kim, Shawn G. Kwatra, Michael E. Kuligowski, May E. Venturanza, Shaoceng Wei, Leon Kircik
Publikováno v:
Journal of the American Academy of Dermatology. 88:651-653
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::741063c655e9834bd7c7449f9cd390cc
https://doi.org/10.1016/j.jaad.2022.09.010
https://doi.org/10.1016/j.jaad.2022.09.010
Autor:
Andrew Blauvelt, Leon Kircik, Kim A. Papp, Eric L. Simpson, Jonathan I. Silverberg, Brian S. Kim, Shawn G. Kwatra, Michael E. Kuligowski, May E. Venturanza, Shaoceng Wei, Jacek C. Szepietowski
Publikováno v:
Journal of the European Academy of Dermatology and Venereology. 37:137-146
Ruxolitinib cream is a topical formulation of ruxolitinib, a Janus kinase (JAK) 1/JAK2 inhibitor.To report timing and magnitude of effect of ruxolitinib cream on itch in patients with atopic dermatitis (AD), a highly pruritic inflammatory skin diseas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fd79211ea0eb8edec513e393a2f2fdf8
https://doi.org/10.1111/jdv.18571
https://doi.org/10.1111/jdv.18571
Publikováno v:
Journal of the American Academy of Dermatology. 82:1305-1313
Atopic dermatitis (AD), a chronic, highly pruritic skin disorder, impairs quality of life (QoL). Janus kinase inhibitors suppress inflammatory and pruritus-associated cytokine signaling in AD.To report the effects of ruxolitinib (RUX) cream on itch a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::249329239ee536c97c1e12fefb142011
https://doi.org/10.1016/j.jaad.2020.02.009
https://doi.org/10.1016/j.jaad.2020.02.009
Autor:
Donald Y.M. Leung, Amy S. Paller, Andrea L. Zaenglein, Wynnis L. Tom, Peck Y. Ong, May E. Venturanza, Michael E. Kuligowski, Qian Li, Xiaohua Gong, Mark S. Lee
Publikováno v:
Annals of Allergy, Asthma & Immunology. 130:500-507.e3
Therapies for children with atopic dermatitis (AD) have safety and tolerability concerns that may limit long-term use. Ruxolitinib cream, a Janus kinase (JAK) inhibitor, is effective and well tolerated in adolescents and adults with AD.The primary ob
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::46fd47ccf03413ea01566fbf5341396e
https://doi.org/10.1016/j.anai.2022.12.033
https://doi.org/10.1016/j.anai.2022.12.033
Autor:
Lawrence F. Eichenfield, Andrew Blauvelt, Leon Kircik, May E. Venturanza, Haobo Ren, Eric L. Simpson
Publikováno v:
Journal of the American Academy of Dermatology. 87:AB202
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9ad29ba24ec2a945ec765f56733b4cb8
https://doi.org/10.1016/j.jaad.2022.06.841
https://doi.org/10.1016/j.jaad.2022.06.841
Autor:
Lawrence F. Eichenfield, Linda F. Stein Gold, Zelma C. Chiesa Fuxench, May E. Venturanza, Haobo Ren, Kanwaljit K. Brar
Publikováno v:
Journal of the American Academy of Dermatology. 87:AB180
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b400b34123ad030b5c41ae1e49691346
https://doi.org/10.1016/j.jaad.2022.06.752
https://doi.org/10.1016/j.jaad.2022.06.752
Autor:
Kang Sun, May E. Venturanza, Eric L. Simpson, Darryl Toth, Donald Y.M. Leung, Seth Forman, Kim A. Papp, Jacek C Szepietowski, Lawrence F. Eichenfield, Michael E. Kuligowski, Leon H Kircik
Publikováno v:
Journal of the American Academy of Dermatology. 85(4)
Ruxolitinib (RUX) cream demonstrated potent anti-inflammatory and antipruritic efficacy in a phase 2 study in adults with atopic dermatitis (AD).To evaluate 8-week efficacy and safety in 2 phase 3 studies of RUX cream in patients with AD.Topical Ruxo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::859983a6040a437db0a1b7c897edc70d
https://pubmed.ncbi.nlm.nih.gov/34153395
https://pubmed.ncbi.nlm.nih.gov/34153395
Autor:
Jonathan I. Silverberg, Andrew Blauvelt, Lawrence Eichenfeld, Kang Sun, May E. Venturanza, Michael E. Kuligowski
Publikováno v:
SKIN The Journal of Cutaneous Medicine. 5:s65
N/A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4578d436cf7a256236471daee3d36764
https://doi.org/10.25251/skin.5.supp.65
https://doi.org/10.25251/skin.5.supp.65
Autor:
May E. Venturanza, Brian S. Kim, Kim Papp, Jonathan I. Silverberg, Jacek C Szepietowski, Andrew Blauvelt, Kang Sun, Shawn G. Kwatra, Eric Simpson, Michael E. Kuligowski, Leon H Kircik
Publikováno v:
SKIN The Journal of Cutaneous Medicine. 5:s64
N/A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::967cac71369cecc5e763aeb15ef8c7c1
https://doi.org/10.25251/skin.5.supp.64
https://doi.org/10.25251/skin.5.supp.64
Autor:
Kim Papp, Darryl Toth, Kang Sun, May E. Venturanza, Eric L. Simpson, Lawrence Eichenfeld, Jacek C Szepietowski, Leon H Kircik, Seth Forman, Michael E. Kuligowski
Publikováno v:
SKIN The Journal of Cutaneous Medicine. 5:s63
N/A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7cc27700eac95989beacb18746bfa046
https://doi.org/10.25251/skin.5.supp.63
https://doi.org/10.25251/skin.5.supp.63